建发致新 reported revenue of ¥10.00B for the period ended 2026-06-30, +1.8% year on year. Net income was ¥0.19B, a 1.9% net margin on a 8.1% gross margin. The largest revenue line is 血管介入 at 53% of the total. Free cash flow for the period was ¥0.43B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥10.00B | +1.8% |
| Gross profit | ¥0.81B | — |
| Operating income | ¥0.29B | — |
| Net income | ¥0.19B | +12.6% |
| Gross margin | 8.1% | Net margin 1.9% |
| Revenue Q/Q | +21.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血管介入 | ¥5.29B | 52.9% |
| 外科器械 | ¥2.22B | 22.2% |
| 检验试剂(IVD) | ¥1.33B | 13.2% |
| 医疗设备 | ¥0.62B | 6.2% |
| 其他医疗器械 | ¥0.32B | 3.2% |
| SPD及其他服务 | ¥0.20B | 2.0% |
| 其他(补充) | ¥0.03B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥9.19B | 91.9% |
| R&D | ¥0.01B | 0.1% |
| SG&A | ¥0.38B | 3.8% |
| Tax & other | ¥0.09B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥16.33B |
| Total liabilities | ¥13.81B |
| Shareholders' equity | ¥2.52B |
| Equity / assets | 15.4% |
| Operating cash flow | ¥0.44B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.43B |
| Cash conversion (OCF / net income) | 39% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
蓝宇股份 ・ 佳力奇 ・ 中瑞股份 ・ 美新科技 ・ 诺瓦星云 ・ 优优绿能 ・ 肯特股份 ・ 六九一二 ・ 太力科技 ・ 瑞迪智驱 ・ 博科测试 ・ 理奇智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies